bluebird presents long-term data from CALD gene therapybluebird bio has produced updated data from its gene therapy for the rare genetic neurological disease cerebral adrenoleukodystrophy Share Xbluebird presents long-term data from CALD gene therapyhttps://pharmaphorum.com/news/bluebird-presents-long-term-data-from-cald-gene-therapy/
Novartis points to Zolgensma long-term benefits amid data scandalNovartis has new data in hand for spinal muscular atrophy (SMA) gene therapy Zolgensma that it hopes will Share XNovartis points to Zolgensma long-term benefits amid data scandalhttps://pharmaphorum.com/news/novartis-points-to-zolgensmas-long-term-benefits-amid-data-scandal/
Roche’s Gazyva wins Breakthrough Therapy status for lupus nephritisRoche’s Gazyva has won Breakthrough Therapy status for its potential new use in the autoimmune disease lupus nephritis, Share XRoche’s Gazyva wins Breakthrough Therapy status for lupus nephritishttps://pharmaphorum.com/news/roches-gazyva-wins-breakthrough-therapy-status-for-lupus-nephritis/
Merck & Co in pole position for Ebola vaccine approval as FDA begins reviewThe FDA is to review Merck & Co’s Ebola vaccine, giving the US pharma a chance to grab Share XMerck & Co in pole position for Ebola vaccine approval as FDA begins reviewhttps://pharmaphorum.com/news/fda-to-review-merck-cos-ebola-vaccine/
Acceleron axes clinical development of muscular dystrophy drugAcceleron has axed clinical development of its ACE-083 in the inherited muscle-wasting disease muscular dystrophy, after the drug Share XAcceleron axes clinical development of muscular dystrophy drughttps://pharmaphorum.com/news/acceleron-axes-clinical-development-of-muscular-dystrophy-drug/
Novartis’ Cosentyx heads for fourth indicationNovartis’ Cosentyx could be heading for a fourth indication after the company published late-stage trial data showing it Share XNovartis’ Cosentyx heads for fourth indicationhttps://pharmaphorum.com/news/cosentyx-heads-for/
Last BACE bombs: Eisai, Biogen give up on elenbecestatThe final BACE inhibitor in clinical testing for Alzheimer’s disease – Eisai and Biogen’s elenbecestat – has been Share XLast BACE bombs: Eisai, Biogen give up on elenbecestathttps://pharmaphorum.com/news/last-bace-bombs-eisai-biogen-give-up-on-elenbecestat/
Tocagen plummets on phase 3 data for glioma therapyA phase 3 trial of Tocagen’s therapy for high-grade glioma (HGG) – a form of brain cancer – Share XTocagen plummets on phase 3 data for glioma therapyhttps://pharmaphorum.com/news/tocagen-plummets-on-phase-3-data-for-glioma-therapy/
Roche preps filings for satralizumab in rare disease NMOSDRoche is two for two in its phase 3 trials programme for satralizumab in the rare disease neuromyelitis Share XRoche preps filings for satralizumab in rare disease NMOSDhttps://pharmaphorum.com/news/roche-preps-filings-for-satralizumab-in-rare-disease-nmosd/
